CN118078810A - 用于抑制肿瘤生长的材料和方法 - Google Patents

用于抑制肿瘤生长的材料和方法 Download PDF

Info

Publication number
CN118078810A
CN118078810A CN202410201525.5A CN202410201525A CN118078810A CN 118078810 A CN118078810 A CN 118078810A CN 202410201525 A CN202410201525 A CN 202410201525A CN 118078810 A CN118078810 A CN 118078810A
Authority
CN
China
Prior art keywords
cancer
formulation
combination
free amino
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410201525.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·维德亚瑟格
R·古普塔
S·加托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entelinco LLC
University of Florida Research Foundation Inc
Original Assignee
Entelinco LLC
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entelinco LLC, University of Florida Research Foundation Inc filed Critical Entelinco LLC
Publication of CN118078810A publication Critical patent/CN118078810A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410201525.5A 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法 Pending CN118078810A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762566787P 2017-10-02 2017-10-02
US62/566,787 2017-10-02
CN201880076756.0A CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法
PCT/US2018/054015 WO2019070750A1 (en) 2017-10-02 2018-10-02 MATERIALS AND METHODS FOR INHIBITING TUMOR GROWTH

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880076756.0A Division CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Publications (1)

Publication Number Publication Date
CN118078810A true CN118078810A (zh) 2024-05-28

Family

ID=64049688

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880076756.0A Active CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法
CN202410201525.5A Pending CN118078810A (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201880076756.0A Active CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Country Status (7)

Country Link
US (1) US12109191B2 (enExample)
EP (1) EP3691628A1 (enExample)
JP (2) JP7352901B2 (enExample)
KR (1) KR102709096B1 (enExample)
CN (2) CN111417391B (enExample)
CA (1) CA3078335A1 (enExample)
WO (1) WO2019070750A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
EP3796922A1 (en) * 2018-05-22 2021-03-31 Seleq Oy Pharmaceutical compositions for the treatment of cancer
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT202000000454A1 (it) * 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
CN115697301A (zh) * 2020-05-29 2023-02-03 佛罗里达大学研究基金会公司 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH01301619A (ja) * 1988-05-30 1989-12-05 Otsuka Pharmaceut Factory Inc 癌用アミノ酸製剤
JPH0368514A (ja) * 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
AU1356692A (en) 1991-09-30 1993-05-03 Devtech Labs, Inc. Electrostatic separation of plastic materials
US5658895A (en) 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
KR0172193B1 (ko) * 1991-10-07 1999-02-01 오오쓰까 아끼히꼬 암 치료용 경장제제
JP3429327B2 (ja) 1992-07-20 2003-07-22 味の素ファルマ株式会社 癌用アミノ酸輸液剤
JPH06256184A (ja) 1993-03-05 1994-09-13 Morishita Roussel Kk 癌患者用アミノ酸製剤
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
EP1789033B1 (en) * 2004-08-09 2019-04-03 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders
JP6000253B2 (ja) 2010-09-24 2016-09-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 胃腸機能を改善するための材料および方法
US20160374971A1 (en) 2013-07-01 2016-12-29 The Trustees Of Princeton University Dietary supplements for treating cancer
AU2016326347B2 (en) * 2015-09-21 2021-02-25 The Board Of Trustees Of The Leland Stanford Junior University Nutritional treatment for cancer

Also Published As

Publication number Publication date
JP7352901B2 (ja) 2023-09-29
KR102709096B1 (ko) 2024-09-23
CN111417391B (zh) 2024-06-18
EP3691628A1 (en) 2020-08-12
CN111417391A (zh) 2020-07-14
JP2023171755A (ja) 2023-12-05
US12109191B2 (en) 2024-10-08
JP2020536096A (ja) 2020-12-10
WO2019070750A1 (en) 2019-04-11
KR20200060492A (ko) 2020-05-29
CA3078335A1 (en) 2019-04-11
US20200323820A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
CN111417391B (zh) 用于抑制肿瘤生长的材料和方法
US9526915B2 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US20100029683A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
AU2016213862B2 (en) Procaspase 3 activation by combination therapy
JP5377968B2 (ja) 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
CN104918630A (zh) 抗药性癌细胞的抑制
CN113194946A (zh) 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
CN105283180A (zh) Pi3k抑制剂与微管去稳定剂的药物组合
TWI834868B (zh) 難治性癌症之預防或治療用之醫藥組合物
WO2020234828A1 (en) Oxathiazin compounds for inhibiting gapdh
CN117377492A (zh) 包含蛋白激酶抑制剂的药物组合物及其医药用途
TWI891650B (zh) 治療血管畸形之方法
JP7468829B2 (ja) 癌を処置するための、癌治療剤と組み合わせたＩＲＥ１α阻害剤
KR20220034505A (ko) 암의 기원 세포의 사멸용 약학적 조성물
JP2022542725A (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
US20220289686A1 (en) Compositions of nrf2 inhibiting agents and methods of use thereof
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
KR20200014880A (ko) 테세탁셀 및 카페시타빈에 대한 투약 일정
US20240122937A1 (en) Treating cancer in patient with pten inactivating mutation
US20180177783A1 (en) Combination therapy using belinostat and pralatrexate to treat lymphoma
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
HK40060452A (en) COMBINED USE OF A-NOR-5α ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Florida, USA

Applicant after: University OF FLORIDA RESEARCH FOUNDATION, INC.

Applicant after: Amylev Limited

Address before: Florida, USA

Applicant before: University OF FLORIDA RESEARCH FOUNDATION, INC.

Country or region before: U.S.A.

Applicant before: Entelinco LLC

CB02 Change of applicant information